Journals & Newsletters:

Cott J (2003). Bipolar disorder: Alternatives to lithium.  J Amer Herbalists Guild 3(2):43-51. PDF copy

Cott J(2002). Press releases freely interpret failed study and claim that St. John’s Wort doesn’t work. HerbalGram. 56:22-23.

Cott J (2002). The effects of Ginkgo biloba in normal memory. The Integrative Medicine Consult 4(10):110.

Cott J (2002). Drug interactions with St. John’s wort.  Alternative Therapies in Women's Health 4(8):60-64.

Cott J, Wisner K. (2002). St. John’s wort and depressive disorder (letter). JAMA 288(4):448. Text Link

Cott J (2002). NIH St. John's Wort Study Fails to Satisfy. The Integrative Medicine Consult 4(7)(July) 73,77,83.

Awang DVC, Cott J, Fugh-Berman A. (2001). Colchicine in ginkgo? Alternative Therapies in Women's Health. 3(10):73-76.

Cott J, Rosenthal N, Blumenthal M (2001). Re: St. John’s wort in major depression. (Letter), JAMA July 4, 286:42. PDF PubMed

Cott J (2001): St. John’s wort: safe and effective? Geriatrics and Aging 4(4):18.

Cott J (2001): Recent trial of St. John's wort creates misunderstandings. HerbalGram 53:17-18.

Cott J, Hibbeln J (2001). Lack of seasonal mood changes in Icelanders. (letter). Amer J Psychiat. 158(2):328. PDF PubMed

Cott J (2001). St. John’s wort and photosensitivity. Alternative Therapies in Women's Health 3(3):20-23.

Cott J (2001). Morinda citrifolia (noni). Alternative Therapies in Women's Health 3(1):5-7.

Cott J (2000). Omega-3 fatty acids and pregnancy. Alternative Therapies in Women's Health 2(12):89-92.

Dominguez RA, Bravo-Valverde RL, Kaplowitz BR, Cott JM (2000): Hypnotic efficacy of valerian in Hispanic patients. Cultural Diversity and Ethnic Minority Psychology. 6(1):84-92. PubMed

Cott J (1999). Omega-3 fatty acids and psychiatric Disorders. Alternative Therapies in Women's Health 1(13):97-104.

Fugh-Berman A, Cott JM (1999). Dietary supplements and natural products as psychotherapeutic agents. Psychosom Med. 61:712-728. (Full text link) (link 2)

Cott JM, Fugh-Berman A (1998). Is St. John's Wort (Hypericum perforatum) an effective antidepressant? Journal of Nervous and Mental Disease 186:500-501. PDF  PubMed

Upton R, Graff A, Williamson E, Bunting D, Gatherum DM, Walker EB, Cott J, et al. (1997) American Herbal Pharmacopoeia and Therapeutic Compendium on St. John’s Wort Hypericum perforatum: Quality control, analytical and therapeutic monograph. HerbalGram 40 (suppl.):1-32.

Cott J (1998). Herbal medicine: Ancient roots to modern medicine. HerbalGram 44:55-56.

Cott J (1997). In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 30 (Suppl.):108-112. PDF  PubMed

Cott J (1995). Natural product formulations available Europe for psychotropic indications. Psychopharm Bulletin 31(4):745-751. PubMed

Cott J (1995). Medicinal Plants and Dietary Supplements: Sources for Innovative Treatments or Adjuncts? Psychopharm Bulletin 31(1):131-137. PubMed

Shore D, Matthews S, Cott J, Lieberman J (1995). The clinical implications of clozapine discontinuation: Report of an NIMH Workshop. Schizophrenia Bulletin 21(2):333-338.

Haigler H, Cott JM, Rudorfer M, Schoenfeld RI, Potter WZ, Vitiello B, Everist HD (1992). Psychotherapeutic Medications Development Program (PMDP). Psychopharm Bulletin 29: 241-247. PubMed

Cott JM, Kurtz NM, Robinson DS, Lancaster SP, Copp JE (1988). A 5-HT_1A ligand, with both antidepressant and anxiolytic properties. Psychopharm Bulletin 24: 164-167. PubMed

Weissman BA, Cott J, Jackson JA, Bolger GT, Weber KH, Horst WD, Paul S, Skolnick P (1985). "Peripheral-Type" binding sites for benzodiazepines in brain: Relationship to the convulsant actions of Ro 5-4864. J Neurochemistry 44: 1491-1499. PubMed

Bolger GT, Mezey E, Cott J, Weissman BA, Paul S, Skolnick P (1984). Differential regulation of "central" and "peripheral" benzodiazepine binding sites in the rat olfactory bulb. Eur J Pharmacol 105: 143-148. PubMed

Weissman BA, Cott J, Hommer D, Paul S, Skolnick P (1984). Electrophysiological, and pharmacological actions of the convulsant benzodiazepine, Ro 5-4864. Eur J Pharmacol 97: 257-263. PubMed

Weissman BA, Cott J, Hommer D, Quirion R, Paul S, Skolnick P (1983). Pharmacological, electrophysiological, and neurochemical actions of the convulsant benzodiazepine Ro 5-4864 (4'-chlordiazepam). Adv Biochem Psychopharmacol 38:139-51. PubMed

Weissman BA, Cott J, Paul SM, Skolnick P (1983). Ro 5-4863: A potent benzodiazepine convulsant. Eur J Pharmacol 90: 149-150. PubMed

Ögren S-Ö, Cott JM, Hall H (1981). Sedative/anxiolytic effects of antidepressants in animals. Acta Psychiat Scand suppl 290, 63: 277-288. PubMed

Cott JM, Ögren S-Ö (1980). Antidepressant drugs and ethanol: Behavioral and pharmacokinetic interactions in mice. J Neural Trans 48: 223-240. PubMed

Cott JM (1977) Brain GABA in the mediation of locomotor activity [proceedings]. West Afr J Pharmacol Drug Res. 4(1):45P. PubMed

Cott JM, Engel J (1977). Antagonism of the analeptic activity of thyrotropin-releasing hormone (TRH) by agents which enhance GABA transmission. Psychopharmacology 52: 145-149. PubMed

Cott JM, Engel J (1977). Suppression by GABAergic drugs of the locomotor stimulation induced by morphine, amphetamine and apomorphine: Evidence for both pre- and post-synaptic inhibition of catecholamine systems. J Neural Trans 40: 253-268. PubMed

Cott JM, Carlsson A, Engel J, Lindqvist M (1976). Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn-Schmiedeberg's Arch Pharmacol 295: 203-209. PubMed

Cott JM, Breese GR, Cooper BR, Barlow TS, Prange AJ (1976). Investigations into the mechanism of reduction of ethanol sleep by thyrotropin-releasing hormone (TRH). J Pharmacol Exp Ther 196: 594-604. PubMed

Breese GR, Cott JM, Cooper BR, Prange AJ, Lipton MA, Plotnikoff NP (1975). Effects of thyrotropin releasing hormone (TRH) on the actions of pentobarbital and other centrally acting drugs. J Pharmacol Exp Ther 193: 11-22. PubMed

Prange AJ, Breese GR, Jahnke GD, Cooper BR, Cott JM, Wilson IC, Lipton MA, Plotnikoff NP (1975). Parameters of alteration of pentobarbital response by hypothalamic polypeptides. Neuropsychobiology 1: 121-131. PubMed

Prange AJ, Breese GR, Jahnke GD, Martin BR, Cooper BR, Cott JM, Wilson IC, Alltop LB, Lipton MA, Bissette G, Nemeroff CB, Loosen PT (1975). Modification of pentobarbital effects by natural and synthetic poly-peptides: Dissociation of brain and pituitary effects. Life Science 16: 1907-1914. PubMed

Cooper BR, Cott JM, Breese GR (1974). Effects of catecholamine depleting drugs and amphetamine on self-stimulation of brain following various 6-hydroxydopamine treatments. Psychopharmacologia 37: 235-248. PubMed

Prange AJ, Breese GR, Cott JM, Martin BR, Cooper BR, Wilson IC, Plotnikoff NP (1974). Thyrotropin releasing hormone: Antagonism of pentobarbital in rodents. Life Sciences, 14: 447-455. PubMed

Breese GR, Cott JM, Cooper BR, Prange AJ, Lipton MA (1974). Antagonism of ethanol narcosis by thyrotropin releasing hormone. Life Sciences 14: 1053-1063. PubMed

Book Chapters:

Cott J  (2005)  “St. John's Wort" in Encyclopedia of Dietary Supplements.  Paul Coates et al., eds., Marcel Dekker, Inc., New York, NY.

Cott J, (2003) Chapter 8.: Interaction of herbs with other medicines: The example of St John’s Wort.  In: Dietary Supplements of Plant Origin: A Nutritional and Health Approach.  Massimo Maffei, Editor; Taylor & Francis Books Ltd., London & New York, p. 171-186.  On Amazon.com

Cass H, Cott J. (2002) Herbal Medicine. In: Alternative and Complementary Therapies in Mental Health. Scott Shannon, Ed.; Academic Press. On Amazon.com

Fugh-Berman A, Cott J. (2001) Herbs and dietary supplements for neurological problems. In: Alternative Medicine in Neurological Illness. Michael Weintraub and Marc Micozzi, Eds.; New York: Churchill Livingstone, pp. 40-50. On Amazon.com

Cott J (2000). Omega-3 fatty acids and psychiatric disorders. In: The Physician’s Guide to Alternative Medicine, Vol. II. American Health Consultants, Thomson Healthcare

Cott J (1996). U.S. Efforts in Natural Products Research. In: Decade of the Brain: India/USA Research in Mental Health and Neurosciences, S. Koslow, R.S. Murthy, GV Coelo, (eds.), Rockville, Maryland: DHHS, pp. 173-183.

Cott JM, Kurtz NM (1987). New Pharmacologic Treatments for Schizophrenia. In: Handbook of Schizophrenia, Vol 2, Neurochemistry and Neuropharmacology of Schizophrenia. F.A. Henn, L.E. DeLisi (eds.), Elsevier, 203-226. On Amazon.com

Weissman BA, Cott JM, Weber KH, Skolnick P (1985). Are "Peripheral-Type" Binding Sites for Benzodiazepines in Brain Related to the Convulsant Actions of Ro 5-4864? In: Endocoids.  Harbans Lal, Frank Labella, Frank Lane (Eds.) Alan R Liss, Inc, 197-203. Om Amazon.com

Weissman BA, Cott J, Hommer D, Quirion R, Paul S, Skolnick P (1983). Pharmacological, electrophysiological, and neurochemical actions of the convulsant benzodiazepine, Ro 5-4864 (4'-chlorodiazepam). In: Benzodiazepine Recognition Site Ligands: Biochemistry and Pharmacology. G. Biggio and E. Costa (eds.), Raven Press, pp. 139-151. On Amazon.com

Breese GR, Cooper BR, Prange AJ, Cott JM, Lipton MA (1974). Interactions of thyrotropin releasing hormone (TRH) with centrally acting drugs. In: The Thyroid Axis, Drugs and Behavior. A.J. Prange (Ed.), Raven Press, pp. 115-127. On Amazon.com

Abstracts / Posters:

Cott JM (1996): In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Phytomedicine 3(suppl 1):101.

Cott J (1996): The NIMH Pharmacologic Treatment Research Program. Presented at the New Clinical Drug Evaluation Unit Program 36th annual meeting, Boca Raton, Florida, May 28-May 31.

Misra R, Cott J (1996): Modern Drug Development from Traditional Medicinal Plants using Radioligand Receptor Binding Assays (RRA). Presented at the Monroe Wall Symposium: Harnessing Biodiversity for Therapeutic Drugs and Foods: Developing Products for the 21st Century, June, 1996.

Misra R, Cott J (1995): Enhancement of GABA_B Receptor Binding by Ayurvedic Medicinal Plants. Presented at New Clinical Drug Evaluation Unit Program 35th annual meeting, Orlando, Florida, May 31-June 3.

Cott J (1994): Medicinal plants: A potential source for new psychotherapeutic Drugs. Neuropsychopharmacology 10(35):761S. Invited presentation at the Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P. Congress XIX), Washington D.C., June, 1994.

Misra R, Cott J, Silverton J, Bhat B, Dev S (1994): Receptor Binding Studies on Ayurvedic Crude Drugs ! II: Terminalia bellericaRoxb. Presented at the Thirty fifth Annual Meeting of the American Society of Pharmacognosy, Halifax, Nova Scotia, Canada, from July 31 - August 4, 1994.

Misra R, Cott J, Shrivastava R, Dev S (1993): Receptor binding studies on Ayurvedic crude drugs ! I: Withania somnifera (L) Dun. Presented at American Society for Pharmacognosy annual meeting, San Diego, July 18-22.

Cott J, Misra R, Dev S (1993): Novel Pharmacologic Profile of Some Psychoactive Medicinal Plant Extracts. Presented at New Clinical Drug Evaluation Unit Program 33rd annual meeting, Boca Raton, Florida, June 1-4.

Cott, J (1993): Hypericum perforatum (St. John's Wort): A naturally occurring anxiolytic/antidepressant? Presented at ACNP [American College of Neuropsychopharmacology], Honolulu, Hawaii, December, 1993.

Milius RA, Cott JM (1992): The NIMH Chemical Synthesis Program: A Resource for Research in Psychopharmacology, in Problems of Drug Dependence, Proceedings of the 54th Ann Meeting, College on Problems of Drug Dependence.

Cott JM, Karp D, Koslow SH (1992): The NIMH Psychopharmacology Research Branch. Presented at the 12/92 American College of Neuropsychopharmacology annual meeting, San Juan, Puerto Rico.

Cott JM, Kurtz NM, Robinson DS, Temple DL (1986): Clinical anxioselective activity of gepirone. Presented at the American Psychiatric Association Annual Meeting, Washington, D.C.

Cott JM, Kurtz NM, Robinson DS, Temple DL (1986): Neuroendocrine response to the 5HT_1A ligand, gepirone, in normal subjects. Presented at the American College of Neuropsychopharmacology Annual Meeting, Washington, D.C.

Kurtz NM, Cott JM, Robinson DS (1985): Clinical and preclinical pharmacology of the putative antipsychotic: BMY 13859. Presented at the IVth World Congress of Biological Psychiatry, (Abst) 206.

Cott JM, Kurtz NM, Robinson DS (1985): Gepirone (BMY 13805): A new analog of buspirone with anxiolytic potential. Presented at the IVth World Congress of Biological Psychiatry, (Abst) 213.

Cott JM, Ögren S-Ö (1980): Antidepressant drugs and ethanol: Behavioral and pharmacokinetic interactions in mice. Presented at the 12th Congress of Collegium Internationale Neuropsychopharmacologicum. Göteborg, Sweden. June 22-26.

Cott JM, Ögren S-Ö, Lindgren J-E, Lundström J (1980): Behavioral and metabolic interactions between antidepressants and sedative-hypnotics in mice. Presented at the 12th Congress of Collegium Internationale Neuropsychopharmacologicum. Göteborg, Sweden. June 22-26.

Cott JM (1977): Brain GABA in the mediation of locomotor activity. West African J Pharmacol Drug Res 4(1): 45p.

Cott JM, Breese GR, Cooper BR, Barlow TS (1975): Cholinergic interactions with the analeptic-like activity of thyrotropin releasing hormone. Federation Proceedings 34: 297.

Breese GR, Cott JM, Cooper BR, Prange AJ (1975): Actions of thyrotropin releasing hormone on centrally acting drugs. Presented at the Sixth International Congress of Pharmacology. Helsinki, Finland. July 20-25.

Cott JM, Cooper BR, Breese GR, Prange AJ, Plotnikoff NP, Lipton MA (1974): Antagonism of ethanol sedation with thyrotropin releasing hormone. Pharmacologist 16: 303.

Breese GR, Cott JM, Cooper BR, Prange AJ, Plotnikoff NP, Lipton MA (1974): Interaction of thyrotropin releasing hormone with various centrally acting depressants. Pharmacologist 16: 249.

Grant LD, Howard JL, Cooper BR, Breese GR, Cott JM (1973): Acquisition and performance of operant tasks following brain catecholamine depletion by 6-hydroxydopamine. Abstracts of the American Psychological Association, Honolulu, Hawaii.

Patents:

Cott JM, Kurtz N, Robinson DS: Method for Alleviation of Primary Depressive Disorders. U.S. Patent 4,771,053. September 13, 1988.

Cott JM, Kurtz N, Robinson DS: Method for Treatment of Melancholic Depression. U.S. Patent Application January 1989.

CottJM, Kurtz N, Robinson DS: The use of buspirone for the treatment of melancholic depression. European Patent Application 90102425.7- February 7, 1990